Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01884285 · ClinicalTrials.gov registry record · Phase 1
AZD8186 First Time In Patient Ascending Dose Study
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
NCT01884285 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 147 participants.
The verdict
NCT01884285, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
Study Summary
This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient/mutated or PIK3CB mutated/amplified advanced solid malignancies as monotherapy and in combination with abiraterone acetate or AZD2014.
Interventions
- DRUG Part A: AZD8186 monotherapy
- DRUG Part B: AZD8186 monotherapy
- DRUG Part C1: Abiraterone acetate combination with AZD8186
- DRUG Part D1: AZD2014 combination with AZD8186
- DRUG Part D2 AZD2014 combination with AZD8186
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2013-07-09 |
| Est. Completion | 2020-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01884285
The ClinicalTrials.gov registry entry for NCT01884285 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Part A: AZD8186 monotherapy is the first listed.
NCT01884285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01884285 about?
NCT01884285 is a clinical study titled "AZD8186 First Time In Patient Ascending Dose Study". This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient/mutated or PIK3CB mutated/amplified advanc...
What is the current status of trial NCT01884285?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2013-07-09. Estimated completion is 2020-02-07.
What interventions are being tested in trial NCT01884285?
The interventions under investigation include: Part A: AZD8186 monotherapy (DRUG), Part B: AZD8186 monotherapy (DRUG), Part C1: Abiraterone acetate combination with AZD8186 (DRUG), Part D1: AZD2014 combination with AZD8186 (DRUG), Part D2 AZD2014 combination with AZD8186 (DRUG).
Who is sponsoring clinical trial NCT01884285?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.